Compass pathways stock forecast.

COMPASS Pathways PLC (CMPS) stock is down -1.77% while the S&P 500 is higher by 1.89% as of 2:59 PM on Thursday, Apr 27. CMPS has fallen -$0.15 from the previous closing price of $8.17 on volume of 236,713 shares. Over the past year the S&P 500 has fallen -1.22% while CMPS has fallen -21.27%. CMPS lost -$0.01 per share the …

Compass pathways stock forecast. Things To Know About Compass pathways stock forecast.

Research COMPASS Pathways' (Nasdaq:CMPS) stock key valuation metrics while comparing it with its industry peers & market side by side. Research COMPASS ... The above table shows the analyst CMPS forecast and predictions for the stock price in 12 month’s time. Date Share Price Average 1Y Price Target Dispersion High Low 1Y Actual …With its shares down by 60% in the last 12 months and a recent layoff affecting 30% of its workforce, it's fair to say that Atai Life Sciences ( ATAI 1.87%) is having a rough go of things lately ...Description. Compass Pathways PLC is a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health. The company is motivated by the need to find better ways …16 ส.ค. 2566 ... ... Price” requirement (as defined in the Nasdaq rules). COMPASS intends to use the net proceeds from the proposed financing to fund its pivotal ...

Oct 18, 2023 · Current. -$0.61. 1 Month Ago. -$0.60. 3 Months Ago. -$0.65. COMPASS Pathways PLC ADR analyst estimates, including CMPS earnings per share estimates and analyst recommendations. The 10 analysts offering 12-month price forecasts for Compass Pathways PLC have a median target of 33.00, with a high estimate of 120.00 and a low estimate of 19.00. This indicates a potential increase of 254.08% from the last recorded price of 9.32. The consensus among 11 polled investment analysts is to buy stock in Compass …Web

Oct 26, 2023 · Compass Pathways Plc stock forecasts for 2023-2027. Date: Open Price: Close Price: Change: Compass Pathways Plc Stock Forecast for 2023: January 2023: 2.04: 1.02-50% ... Psychedelics biotech giant COMPASS Pathways (NASDAQ: CMPS) has entered into a securities purchase agreement for an initial $125 million and potential additional of $160 million, with a select ...

Overall, the consensus among analysts is that Compass Pathways has a promising future ahead. CMPS Stock Analysis: Fluctuating Prices and Negative Earnings Growth, but Positive Forecast for the Future. On May 11, 2023, CMPS stock opened at the same price as the previous close, which was 8.59. Throughout the day, the stock’s price fluctuated ...Compass Pathways. Compass Pathways’ roots go back to 2015, when George Goldsmith and Ekaterina Malievskaia founded a nonprofit organization, the Compass Trust Limited, to support research and ...COMPASS Pathways's earnings are forecast to decline at 2.7% per annum while its annual revenue is expected to grow at 82.4% per year. EPS is expected to grow …COMPASS Pathways plc (CMPS) share price prediction for 2023, 2024, 2025, 2026 and 2027. CMPS one year forecast. Compass Pathways Plc stock monthly and weekly forecasts.Web

Research COMPASS Pathways' (Nasdaq:CMPS) stock key valuation metrics while comparing it with its industry peers & market side by side. Research COMPASS ... The above table shows the analyst CMPS forecast and predictions for the stock price in 12 month’s time. Date Share Price Average 1Y Price Target Dispersion High Low 1Y Actual …

COMPASS Pathways is a market leader in the listed psychedelics space and the company has made significant advances over the last few years. COMPASS is burning through cash at a high rate relative ...

COMPASS Pathways is a business that is trying to treat a serious form of depression ... Patents, Financials, and Forecast. COMPASS is pre ... COMPASS Pathways is an extremely risky stock, ...6.0%. 10% most volatile stocks in US Market. 15.3%. 10% least volatile stocks in US Market. 2.9%. Stable Share Price: CMPS is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 9% a week. Volatility Over Time: CMPS's weekly volatility (9%) has been stable over the past year.Find the latest COMPASS Pathways Plc - American CMPS analyst stock forecast, price target, and recommendation trends with in-depth analysis from research reports. Date Range. investment rating ...WebAt close: 04:00PM EST. 6.06 0.00 (0.00%) After hours: 07:09PM EST. Find the latest COMPASS Pathways plc (CMPS) stock discussion in Yahoo Finance's forum. Share your opinion and gain insight from ...Compass Pathways PLC is a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health. The company is motivated by the need to find better ways to help and empower people suffering with mental health challenges who are not helped by existing therapies, and are pioneering the development of a ...

Stock analysis for Compass Pathways Plc (CMPS:NASDAQ GS) including stock price, stock chart, company news, key statistics, fundamentals and company profile.Compass Pathways Plc ADR (CMPS) shares have gone down -22.59% during the last six months, with a year-to-date growth rate less than the industry average at -3.70% against 5.90. Yet analysts are ramping up their growth forecast for the fiscal year 2023. Revenue is predicted to grow 64.40% this quarter and then jump 7.00% in the …WebView Our Latest Research Report on COMPASS Pathways. COMPASS Pathways Price Performance. COMPASS Pathways stock opened at $6.01 on Friday. The firm has a market cap of $372.02 million, a P/E ratio of -2.32 and a beta of 2.56. The stock’s 50 day moving average is $6.75 and its 200 day moving average is $7.90.According to 5 stock analysts, the average 12-month stock price forecast for CMPS stock stock is $49.6, which predicts an increase of 722.55%. The lowest target is $19 and the highest is $120. On average, analysts rate CMPS stock stock as a strong buy.COMPASS Pathways has a market cap of $299.3 million, and a 52-week range of $6.74 to $49.52. The stock has a price/book ratio of 1.32, and a price-to-free-cash-flow ratio of -6.9.WebMay 13, 2022 · COMPASS Pathways has a market cap of $299.3 million, and a 52-week range of $6.74 to $49.52. The stock has a price/book ratio of 1.32, and a price-to-free-cash-flow ratio of -6.9.

COMPASS Pathways is a market leader in the listed psychedelics space and the company has made significant advances over the last few years. COMPASS is burning through cash at a high rate relative ...Compass Pathways initiates UK component of global phase 3 study of psilocybin treatment in treatment-resistant depression, and launches new research center. Read more. Compass is a biotechnology company dedicated to accelerating patient access and experience to evidence-based innovation in mental health care.Web

Shares of Compass Pathways (CMPS 6.61%) have soared since the company's recent stock market debut as support grows for the use of popular recreational drugs to combat depression.Nov 11, 2021 · Compass Pathways Plc. Market Cap. $399M. Today's Change. (6.61%) $0.40. Current Price. $6.45. Price as of November 24, 2023, 1:00 p.m. ET. You’re reading a free article with opinions that may ... Get a real-time COMPASS Pathways plc (CMPS) stock price quote with breaking news, financials, statistics, charts and more.Dec 1, 2023 · COMPASS Pathways (CMPS) Stock Forecast & Price Target $6.05 +0.22 (+3.77%) (As of 11/22/2023 ET) Compare Today's Range $5.80 $6.07 50-Day Range $5.27 $9.92 52-Week Range $5.01 $11.48 Volume 169,831 shs Average Volume 347,447 shs Market Capitalization $374.50 million P/E Ratio N/A Dividend Yield N/A Price Target $46.83 Discover COMPASS Pathways' earnings and revenue growth rates, forecasts, and the latest analyst predictions while comparing them to its industry peers.And the biotechnology industry's average price-to-sales multiple is 4.7. Thus, if Compass manages to capture a mere 10% of that per year, it could be bringing in $139 million in revenue. Assuming ...WebEF Hutton analyst Elemer Piros reiterated a Buy rating on COMPASS Pathways (CMPS – Research Report) today and set a price target of $38.00... EF Hutton analyst Elemer Piros reiterated a Buy rating on COMPASS Pathways (CMPS – Research ...

On Nov 02, 2023, Compass Pathways ( NASDAQ: CMPS) reported Q3 2023 earnings per share (EPS) of -$0.67, up 55.81% year over year. Total Compass Pathways earnings for the quarter were -$33.39 million. In the same quarter last year, Compass Pathways 's earnings per share (EPS) was -$0.43. If you're new to stock investing, here's how to buy …

Fresh off IPO, Compass sees mushrooming opportunity in psilocybin....CMPS Psychedelic company Compass Pathways PLC (CMPS) got off to a stellar start of trading on Friday, as investors hungry for the next new thing bought up shares. The U.K....

Next reporting date. March 27, 2024. EPS forecast (this quarter) -$0.22. Annual revenue (last year) $233.0K. Annual profit (last year) -$152.4M.COMPASS Pathways EBIT Forecast for 2023 - 2025 - 2030. In the last year, COMPASS Pathways's EBIT has grown from $-47.15M to $-73.57M – a 56.03% increase. For the …69.32%. Get the latest Compass Pathways PLC (CMPS) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions.Bid Price and Ask Price. The bid & ask refers to the price that an investor is willing to buy or sell a stock. The bid is the highest amount that a buyer is ...That's true for all of the existing public psychedelic biotechs engaged in drug development, including such industry leaders as Compass Pathways (CMPS-2.26%) and Atai Life Sciences (ATAI-1.51%).1 de jul. de 2023 ... While Compass Pathways' (CMPS 2.17%) stock is near $8, the analysts on Wall Street are figuring, on average, that its shares will explode by ...The only companies that have Phase 2 clinical trials now are Compass Pathways, Mind Medicine, Cybin, and Mydecine Innovations....CMPS With so many new IPOs and companies launching in the psychedelic industry it's important to fully evaluate...COMPASS Pathways' (NASDAQ:CMPS) Phase 2b study of synthetic psilocybin COMP360 paired with psychological support for Treatment-Resistant ... COMPASS Pathways' (NASDAQ:CMPS) Phase 2b study of synthetic psilocybin COMP360 paired with...People use statistics daily for weather forecasts, predicting disease, preparing for emergencies, medical research, political campaigns, tracking sales, genetics, insurance, the stock market and quality testing.17 de out. de 2022 ... Math over Myth is your weekly source for psychedelic stock updates, including Compass Pathways and Revive Therapeutics.Kabir Nath, COMPASS Pathways Chief Executive Officer said, ... sold its remainder position on Friday for $121.6 million, according to disclosure by the local Indian stock exchange.Aug 16, 2023 · Psychedelics biotech giant COMPASS Pathways (NASDAQ: CMPS) has entered into a securities purchase agreement for an initial $125 million and potential additional of $160 million, with a select ...

The consensus 12-month price target for Compass Pathways reflects an upside potential of close to 325%. Even the most pessimistic analyst surveyed by Refinitiv thinks that the stock will double ...WebHow to buy COMPASS Pathways PLC stock on Stash. 1. Enter the amount you'd like to invest in COMPASS Pathways PLC stock, then proceed to checkout. Stash allows you to purchase smaller, more affordable pieces of investments (called fractional shares) rather than the whole share, which can be significantly more expensive.Compare with up to 5 Stocks. On Thursday 11/30/2023 the closing price of the COMPASS Pathways PLC (spons. ADRs) share was $6.20 on NAS. Compared to the opening price on Thursday 11/30/2023 on NAS ... 18 ก.ย. 2563 ... That was up from initial expectations for $14-$16 announced earlier in the week, putting the valuation at about $544 million. Compass said it ...Instagram:https://instagram. lucid ev stock pricegle coupe 20242009 lincoln centsbest book on options trading for beginners Compass Pathways to participate in upcoming Evercore investor conference. LONDON, Nov. 24, 2023 (GLOBE NEWSWIRE) -- Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that management will hold a fireside chat … temu crocsdirexion etf list It's a gradual path, however, and the stock hasn't moved much overall since the company last provided a financial update on Aug. 11. But in the month of September, Compass shares slid 11.9% ... auroracannabis stock Jul 1, 2023 · While Compass Pathways' (CMPS 0.84%) stock is near $8, the analysts on Wall Street are figuring, on average, that its shares will explode by 458% to reach around $42.30 within the next 12 months. Analyst Price Forecast Suggests 309.83% Upside. As of April 6, 2023, the average one-year price target for COMPASS Pathways Plc American Depository Shares is $42.38. The forecasts range from a low ...Web